2017
DOI: 10.1016/j.bmcl.2017.05.084
|View full text |Cite
|
Sign up to set email alerts
|

Multifunctional human serum albumin-therapeutic nucleotide conjugate with redox and pH-sensitive drug release mechanism for cancer theranostics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
47
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

5
3

Authors

Journals

citations
Cited by 31 publications
(54 citation statements)
references
References 31 publications
0
47
0
Order By: Relevance
“…HSA is the most abundant protein in blood plasma and is widely used as a drug carrier . Fullerenes show a great potential in numerous biological and medicinal applications and their binding with proteins enhances solubility in water and might facilitate transport to the target sites .…”
Section: Methodsmentioning
confidence: 99%
“…HSA is the most abundant protein in blood plasma and is widely used as a drug carrier . Fullerenes show a great potential in numerous biological and medicinal applications and their binding with proteins enhances solubility in water and might facilitate transport to the target sites .…”
Section: Methodsmentioning
confidence: 99%
“…HSA readily crosses blood-vessel and blood-brain barriers and can accumulate in tumors; hence HSA conjugates can be injected remotely from sensitive organs/tissues and be delivered by the circulation. The properties of HSA are preserved when conjugated with HTL or its derivatives [40,47,77] (and see above), and could be exploited with ORCAs to specifically enhance contrast for tumors. HSA-based constructs often bind to albondin on the endothelium and SPARC in the tumor interstitium, thereby accumulating in and highlighting tumors, including brain tumors (glioma) [32,40,47,77,78].…”
Section: Characterization Of Hsa-nit Magnetic Propertiesmentioning
confidence: 99%
“…The properties of HSA are preserved when conjugated with HTL or its derivatives [40,47,77] (and see above), and could be exploited with ORCAs to specifically enhance contrast for tumors. HSA-based constructs often bind to albondin on the endothelium and SPARC in the tumor interstitium, thereby accumulating in and highlighting tumors, including brain tumors (glioma) [32,40,47,77,78]. Finally, the lifetime of HSA in the body is about 25 days with a normal turnover of more than 10 g per day [79], readily accommodating the HSA added by a conjugate optimized for use as an ORCA.…”
Section: Characterization Of Hsa-nit Magnetic Propertiesmentioning
confidence: 99%
“…Due to continuous blood circulation and low immunological effect HSA is successfully used as a core to improve the potential of therapeutic agents [12][13][14][15][16][17][18][19]. The binding of BODIPY residues to proteins is a rather recent topic for research.…”
Section: Bioconjugationmentioning
confidence: 99%